Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Liabilities and Shareholders Equity (2021 - 2025)

Kezar Life Sciences' Liabilities and Shareholders Equity history spans 5 years, with the latest figure at $125.3 million for Q1 2025.

  • For Q1 2025, Liabilities and Shareholders Equity fell 37.1% year-over-year to $125.3 million; the TTM value through Sep 2025 reached $269.9 million, down 64.68%, while the annual FY2024 figure was $144.7 million, 34.6% down from the prior year.
  • Liabilities and Shareholders Equity for Q1 2025 was $125.3 million at Kezar Life Sciences, down from $144.7 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $317.5 million in Q2 2022 and bottomed at $125.3 million in Q1 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $217.9 million (2021), against an average of $214.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 132.85% in 2022 before it plummeted 37.1% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $217.9 million in 2021, then surged by 37.46% to $299.6 million in 2022, then fell by 26.15% to $221.2 million in 2023, then crashed by 34.6% to $144.7 million in 2024, then dropped by 13.42% to $125.3 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Liabilities and Shareholders Equity are $125.3 million (Q1 2025), $144.7 million (Q4 2024), and $164.1 million (Q3 2024).